Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

Kelsey K. Baker

24 indexed publications match this author name.

ORCID: 0000-0002-8062-8839
OpenAlex: https://openalex.org/A5041041464

Author watchlist

Create a confirmed email alert for new publications matching this author.

Topics

Depression 14 Receptor Pharmacology 11 Clinical Trial 10 Safety 10 Mechanism of Action 6 Neuroplasticity 5 Randomized Controlled Trial 5 Observational Study 5 Chronic Pain 4 Review Article 4 Treatment-Resistant Depression 4 Adverse Events 4

Journals

Psychological medicine 2 Irish journal of psychological medicine 2 The New England journal of medicine 2 bioRxiv: the preprint server for biology 1 Cell Reports Medicine 1 Molecular psychiatry 1 Zenodo (CERN European Organization for Nuclear Research) 1 Psychedelic Medicine 1

Publication history

Dissociating the Hallucinogenic and Neuroplastic Effects of Psilocybin.bioRxiv: the preprint server for biology · 2026-07-09 Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-07-01 Psilocybin mitigates chronic behavioral and neurobiological alterations in a rat model of recurrent intimate partner violence-related brain injury.Molecular psychiatry · 2026-04-01 The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidenceZenodo (CERN European Organization for Nuclear Research) · 2026-01-26 Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 StudyPsychedelic Medicine · 2026-01-18 Sex-dependent effects of psychedelics: review of evidence from rodent models.Frontiers in psychiatry · 2026-01-01 Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.Psychopharmacology · 2025-07-01 Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use.British journal of pain · 2025-06-01 Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic Use.Journal of psychoactive drugs · 2025-01-01 Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.JAMA network open · 2024-12-02 Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trialPsyArXiv · 2024-11-04 Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.EClinicalMedicine · 2024-10-01 Psilocybin vs Escitalopram for depression: 6-month follow-upNeuroscience Applied · 2024-01-01 Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.Psychological medicine · 2024-01-01 Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM.Psychological medicine · 2024-01-01 An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations.The American journal of hospice & palliative care · 2023-11-01 The psychedelic renaissance: the next trip for psychiatry?Irish journal of psychological medicine · 2022-12-01 Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.The New England journal of medicine · 2022-11-03 Counselors’ attitudes toward psychedelics and their use in therapyJournal of Counseling & Development · 2022-03-19 Psychedelic science in post-COVID-19 psychiatry.Irish journal of psychological medicine · 2021-06-01 Trial of Psilocybin versus Escitalopram for Depression.The New England journal of medicine · 2021-04-15 Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.Journal of psychopharmacology (Oxford, England) · 2021-04-01 Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.Frontiers in pharmacology · 2021-01-01 Molecular structures of hallucinogenic substances: lysergic acid diethylamide, psilocybin, and 2,4,5-trimethoxyamphetamine.Molecular pharmacology · 1973-01-01

Author directory